Organon & Business Summary

Organon & Co. (OGN) is a global healthcare company primarily focused on women’s health, generating revenue through the commercialization of a diverse pharmaceutical portfolio across three core segments: Women’s Health, Biosimilars, and Established Brands. The company’s revenue model is driven by product sales, with 2026 guidance projecting approximately $6.2 billion in total sales, anchored by its flagship long-acting contraceptive Nexplanon and a robust suite of fertility treatments. While the Established Brands segment—comprising over 60 legacy products in cardiovascular and respiratory health—provides significant cash flow, the company is aggressively pivoting toward its Biosimilars division, which includes immunology and oncology treatments like Hadlima. Organon competes directly with diversified pharmaceutical entities such as Viatris, Bayer AG, and Teva Pharmaceuticals, distinguishing itself as the only major global player with a dedicated strategic focus on female-specific therapeutic areas. The company’s leadership is currently in a transitional phase following the late 2025 resignation of founding CEO Kevin Ali. Joseph Morrissey, a 30-year veteran of Merck & Co., serves as Interim Chief Executive Officer, supported by Executive Chair Carrie S. Cox, who previously held senior leadership roles at Schering-Plough and Bristol-Myers Squibb. The executive team includes Chief Financial Officer Matthew Walsh and Head of R&D Juan Camilo Arjona Ferreira, M.D. This team is currently executing a remediation plan following an internal investigation into wholesaler sales practices while prioritizing a deleveraging strategy to reduce the company’s substantial debt load. Organon’s strategic direction is heavily influenced by major institutional shareholders, including The Vanguard Group, BlackRock, and State Street Corporation, who maintain significant positions in the 2021 Merck spinoff.